NodThera touts po­ten­tial weight loss ef­fect of NL­RP3 in­hibitors

NodThera is mov­ing its NL­RP3 in­hibitors in­to the clin­ic af­ter pre­clin­i­cal da­ta showed it re­versed obe­si­ty and in­flam­ma­tion in mice in a study that com­pared it against No­vo Nordisk’s We­govy.

In the tri­al, mice re­ceiv­ing NT-0796, NodThera’s lead can­di­date, lost 19% of their start­ing body weight by 28 days — com­pa­ra­ble to mice who took semaglu­tide, which lost 21.5% of weight over the same time pe­ri­od.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.